Glioma
Glioma is a broad category of primary central nervous system tumors arising from glial lineage cells in the brain and spinal cord.
Glioma is a broad category of primary central nervous system tumors arising from glial lineage cells in the brain and spinal cord. It includes biologically and clinically diverse entities, ranging from lower-grade diffuse gliomas to highly aggressive forms such as glioblastoma. In recent research, glioma is consistently described as a highly malignant, invasive, and recurrent brain cancer with poor prognosis, substantial therapeutic resistance, and a strongly immunosuppressive tumor microenvironment.
Molecularly, glioma research increasingly focuses on alterations such as IDH mutation status, BRAF alterations, met/c-met signaling, Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB) pathway activity, ferroptosis-related mechanisms, immune evasion, and metabolic reprogramming, including methionine and glucose metabolism. The disease is also a major target for advanced imaging, radiogenomics, liquid biopsy, and precision oncology approaches aimed at improving diagnosis, molecular classification, prognosis, and treatment selection.
Where the papers sit
12 papers from the last 6 months study glioma directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 1 observational · 2 human data · 6 preclinical · 3 unclassified
Themes 3 themes · 1 paradigm shift
-
Glioma Therapeutic Development
Management strategies range from temozolomide toxicity monitoring and partial-tumor irradiation to nucleic-acid delivery with targeted ionizable lipids. H3K27M-driven OPC stemness is being linked to intrathecal therapeutic vulnerability, while SIL1 is assessed as a prognostic biomarker. The common aim is to improve treatment selection, delivery, or safety, but the approaches do not converge on one modality or mechanism. Clinical validation of biomarkers, delivery systems, and focal irradiation remains the main gap.
5 papers · 41.7%
-
Immune Microenvironment in Glioma
Therapy is moving toward treating glioma as an ecosystem shaped by hypoxia, malignant-cell states, and spatially organized immune niches. GliomaDeconv and spatial analysis define cellular programs across progression, while immunotherapy studies emphasize tumor-draining lymph-node B-cell responses. CAR-T designs are adapting to antigen heterogeneity, and cyclophosphamide is being repurposed with chitosan nanoparticles as chemo-immunotherapy. The key unresolved issue is whether these microenvironment-directed combinations can produce durable control across evolving tumors.
5 papers · 41.7%
-
MRI Brain Tumor Imaging
MRI analysis is moving toward attention-based, dual-stream, and transformer architectures for more robust brain-tumor segmentation and classification. U-Net variants target sensitivity to tumor boundaries in clinical scans, while hybrid ConvNeXt-Swin models classify tumor types. Segmentation and classification remain complementary clinical tasks rather than competing endpoints. Generalization across imaging conditions and reliable performance in routine practice remain open challenges.
2 papers · 16.7%
Effective glioma immunotherapy depends on mobilizing immune responses beyond the tumor itself
The CTLA-4 blockade study in glioma-bearing mice 42430444Jul and the armored CAR-T study in antigen-heterogeneous orthotopic glioma 42159488May instead identify host immune cooperation as a therapeutic requirement or mechanism: CTLA-4 efficacy required germinal-center B-cell responses in tumor-draining cervical lymph nodes and antibody accumulation in the tumor, while cytokine-armored CAR-T cells were designed to reverse local immunosuppression and engage endogenous immunity. This challenges the framing of glioma treatment as primarily a problem of delivering cytotoxic agents or engineered cells across tumor barriers and shows that effective therapy can depend on activating immune circuits outside the tumor and coordinating them with local antitumor activity.
Papers
The 12 papers from the last 6 months that study glioma directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Glioma Therapeutic Development (5)
- Dual-drug conjugated ionizable lipids for nucleic acid delivery and multidimensional targeted therapy of brain tumors. International journal of pharmaceutics · 27 Sept 2026 PMID 42801996
- H3K27M drives OPC stemness and intrathecal therapeutic vulnerability in brainstem glioma organoids. Cell stem cell · 16 Sept 2026 PMID 42748922
- Multifaceted Temozolomide Toxicity in Glioma: Detection & Care. La Clinica terapeutica · 28 Aug 2026 PMID 42664125
- Assessing the prognostic value of SIL1 in pan-cancer cohorts and its practical application as a biomarker in glioma practice. BMC cancer · 29 Jun 2026 PMID 42374254
- PATHY-inspired partial tumor irradiation on a small-animal irradiator: workflow development and first therapeutic evaluation in glioma. Physics in medicine and biology · 22 May 2026 PMID 42173137
Immune Microenvironment in Glioma (5)
- Spatial analysis reveals the evolving organization of IDH-mutant glioma. Cancer cell · 14 Sept 2026 PMID 42735681
- The efficacy of immunotherapy in glioma requires distal B cell responses in tumor-draining lymph nodes. Science immunology · 10 Jul 2026 PMID 42430444
- GliomaDeconv maps glioma-specific cellular programs from bulk transcriptomic profiles and reveals spatiotemporal associations with progression and treatment response. Cancer letters · 7 Jul 2026 PMID 42413813
- Repurposing of cyclophosphamide as a chemo‑immunotherapy agent in glioma using D8/RI‑VAP modified-chitosan nanoparticles. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 24 Jun 2026 PMID 42341589
- Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma. Cancer research · 20 May 2026 PMID 42159488
MRI Brain Tumor Imaging (2)
- W-AGRU-Net: a dual-stream attention framework for robust brain tumor segmentation in clinical MRI imaging. Scientific reports · 27 Aug 2026 PMID 42660973
- A novel hybrid transformer-based framework (H-ConvNeXt-Swin) to classify brain tumors using MRI. Scientific reports · 5 Aug 2026 PMID 42557264
By study type
Observational studies and case reports (1)
- Multifaceted Temozolomide Toxicity in Glioma: Detection & Care. La Clinica terapeutica · 28 Aug 2026 PMID 42664125
Human data, design not indexed (2)
- W-AGRU-Net: a dual-stream attention framework for robust brain tumor segmentation in clinical MRI imaging. Scientific reports · 27 Aug 2026 PMID 42660973
- A novel hybrid transformer-based framework (H-ConvNeXt-Swin) to classify brain tumors using MRI. Scientific reports · 5 Aug 2026 PMID 42557264
Preclinical: animal, cell and lab studies (6)
- Spatial analysis reveals the evolving organization of IDH-mutant glioma. Cancer cell · 14 Sept 2026 PMID 42735681
- The efficacy of immunotherapy in glioma requires distal B cell responses in tumor-draining lymph nodes. Science immunology · 10 Jul 2026 PMID 42430444
- GliomaDeconv maps glioma-specific cellular programs from bulk transcriptomic profiles and reveals spatiotemporal associations with progression and treatment response. Cancer letters · 7 Jul 2026 PMID 42413813
- Repurposing of cyclophosphamide as a chemo‑immunotherapy agent in glioma using D8/RI‑VAP modified-chitosan nanoparticles. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 24 Jun 2026 PMID 42341589
- PATHY-inspired partial tumor irradiation on a small-animal irradiator: workflow development and first therapeutic evaluation in glioma. Physics in medicine and biology · 22 May 2026 PMID 42173137
- Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma. Cancer research · 20 May 2026 PMID 42159488
Unclassified: not yet indexed with MeSH (3)
- Dual-drug conjugated ionizable lipids for nucleic acid delivery and multidimensional targeted therapy of brain tumors. International journal of pharmaceutics · 27 Sept 2026 PMID 42801996
- H3K27M drives OPC stemness and intrathecal therapeutic vulnerability in brainstem glioma organoids. Cell stem cell · 16 Sept 2026 PMID 42748922
- Assessing the prognostic value of SIL1 in pan-cancer cohorts and its practical application as a biomarker in glioma practice. BMC cancer · 29 Jun 2026 PMID 42374254
Written from 12 PubMed abstracts, each one listed by PMID above. Published: 2026-07-12. Last written: 2026-09-18 by GPT. Drafted by language models from published abstracts; not medical advice.